USFDA issues Form 483 to Lupin with 2 observations: Nagpur

"We are confident of addressing the observations raised, and will work with the USFDA to resolve them at the earliest," Lupin said.

219
USFDA Form 483
USFDA Form 483

Last Updated on October 6, 2024 by The Health Master

Lupin, on July 12 has informed that United States Food and Drug Administration (USFDA) inspected its Nagpur Oral Solid Dosage facility from July 3 to July 11, 2023.

The inspection closed with issuance of a Form 483 with two observations.

“We are confident of addressing the observations raised, and will work with the USFDA to resolve them at the earliest,” Lupin said.

“We uphold quality and compliance issues with utmost importance and remain committed to be compliant with CGMP quality standards across all our facilities,” the company added.

On July 11, the  company received the establishment inspection report (EIR) from USFDA for its Pithampur Unit-2 manufacturing facility that manufactures oral solids and ophthalmic dosage forms.

The EIR was issued post the last inspection of the facility conducted from March 21 to March 29, 2023.

The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI).

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news